Literature DB >> 24008306

Acquired haemophilia A: a 2013 update.

Massimo Franchini1, Pier Mannuccio Mannucci.   

Abstract

Acquired haemophilia A (AHA) is a rare but often severe bleeding disorder caused by autoantibodies against coagulation factor VIII (FVIII). AHA occurs more frequently in the elderly and in association with several conditions, such as the post-partum period, malignancies, autoimmune diseases or drug exposure; however, approximately 50% of reported cases are apparently idiopathic. Beside the elimination of the underlying disorder, the therapeutic approach to AHA should be directed toward the control of acute bleed and the eradication of FVIII autoantibody production. In this narrative review, we summarise the current knowledge on the epidemiology, diagnosis and clinical features of AHA, focusing in particular on advances in the management of this challenging bleeding disorder.

Entities:  

Keywords:  Acquired haemophilia A; FVIII; auto-antibodies; bleeding; inhibitors; therapy

Mesh:

Substances:

Year:  2013        PMID: 24008306     DOI: 10.1160/TH13-05-0363

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  30 in total

Review 1.  Role of rituximab in the treatment of postpartum acquired haemophilia A: a systematic review of the literature.

Authors:  Carlo Bonfanti; Silvia Crestani; Francesco Frattini; Cinzia Sissa; Massimo Franchini
Journal:  Blood Transfus       Date:  2014-12-17       Impact factor: 3.443

2.  Acquired inhibitors of clotting factors: AICE recommendations for diagnosis and management.

Authors:  Massimo Franchini; Giancarlo Castaman; Antonio Coppola; Cristina Santoro; Ezio Zanon; Giovanni Di Minno; Massimo Morfini; Elena Santagostino; Angiola Rocino
Journal:  Blood Transfus       Date:  2015-06-24       Impact factor: 3.443

3.  Severe non-traumatic bleeding, the answer is not in the blood.

Authors:  Marco Tana; Claudio Tana; Paolo Amerio; Gianfranco Vitullo; Paolo di Giosia; Concetta di Febbo; Giovanni Davì
Journal:  Intern Emerg Med       Date:  2015-02-26       Impact factor: 3.397

4.  Management of bleeding in acquired haemophilia A with recombinant activated factor VII: does one size fit all? A report of four cases.

Authors:  Mirko Di Capua; Antonio Coppola; Assunta Nardo; Ernesto Cimino; Matteo N D Di Minno; Antonella Tufano; Rosaria Mormile; Maria L Burzo; Giovanni Di Minno; Anna M Cerbone
Journal:  Blood Transfus       Date:  2014-06-19       Impact factor: 3.443

Review 5.  Violating the theory of single gene-single disorder: inhibitor development in hemophilia.

Authors:  Suad AlFadhli; Rasheeba Nizam
Journal:  Indian J Hematol Blood Transfus       Date:  2014-11-20       Impact factor: 0.900

Review 6.  Porcine recombinant factor VIII: an additional weapon to handle anti-factor VIII antibodies.

Authors:  Pier Mannuccio Mannucci; Massimo Franchini
Journal:  Blood Transfus       Date:  2016-07-25       Impact factor: 3.443

7.  Acquired haemophilia A: an unusual postoperative complication.

Authors:  Sumant Arora; Gaurav Goyal; Rehan Sarmad; Kenneth J Wool
Journal:  BMJ Case Rep       Date:  2016-11-16

8.  CD4 T cells specific for factor VIII are present at high frequency in healthy donors and comprise naïve and memory cells.

Authors:  Sylvain Meunier; Catherine Menier; Elodie Marcon; Sébastien Lacroix-Desmazes; Bernard Maillère
Journal:  Blood Adv       Date:  2017-09-25

9.  First report of real-time monitoring of coagulation function potential and IgG subtype of anti-FVIII autoantibodies in a child with acquired hemophilia A associated with streptococcal infection and amoxicillin.

Authors:  Masahiro Takeyama; Keiji Nogami; Takahiro Kajimoto; Kenichi Ogiwara; Tomoko Matsumoto; Midori Shima
Journal:  Int J Hematol       Date:  2017-06-08       Impact factor: 2.490

10.  Immune-mediated syndromes following intravenous bisphosphonate therapy.

Authors:  Noa Markovits; Ronen Loebstein; Ilan Bank
Journal:  Inflammopharmacology       Date:  2017-05-31       Impact factor: 4.473

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.